ClinicalTrials.gg
CompletedNCT02500381ESSENCEUpdated Nov 18, 2025

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

A Phase 3 interventional study of SRP-4045 and SRP-4053 in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 76 sites in 24 countries. Open to male participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
6 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
2nd of 25
228 · median 24
Started
2016
the only one that year
Phase 3
7 of 27
1 open now
Registered
8th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2016, is one of 7 in phase 3, and was the 8th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.

Read the detailed description

This is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of SRP-4045 and SRP-4053. Eligible participants with out-of-frame deletion mutations amenable to exon 45 or 53 skipping will be randomized to receive once weekly intravenous (IV) infusions of 30 milligrams/kilograms (mg/kg) SRP-4045 or 30 mg/kg SRP-4053 respectively (combined-active group) or placebo for up to 96 weeks (the placebo-controlled period of the trial). This will be followed by an open-label extension period in which all participants will receive open-label active treatment for 48 weeks (up to Week 144 of study).

The study will enroll approximately 222 participants. Twice as many participants will be randomized to receive active treatment as will receive placebo (2:1 randomization).

Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests, such as the 6-minute walk test (6MWT). All participants will undergo a muscle biopsy at baseline and a second muscle biopsy either at Week 48 or Week 96.

Safety will be assessed through the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations throughout the study.

Blood samples will be taken periodically throughout the study to assess the pharmacokinetics of both drugs.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
  • DMD
  • Exon 53
  • Exon 45
  • Ambulatory
  • Pediatric
  • Duchenne
04

Who can participate

Ages eligible
6 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53 skipping
  • Stable dose of oral for at least 24 weeks prior to Week 1, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).
  • Intact right and left biceps brachii muscles or 2 alternative upper arm muscle groups
  • Mean 6MWT ≥300 meters and ≤450 meters
  • Stable pulmonary function: forced vital capacity (FVC) ≥50% predicted

Exclusion criteria

Exclusion Criteria:

  • Treatment with gene therapy at any time
  • Previous treatment with SMT C1100 within 1 week prior to Week 1 and previous treatment with PRO045 (BMN 045), PRO053 (BMN 053), or PRO051 (BMN 051) within 24 weeks prior to Week 1
  • Current or previous treatment with any other experimental treatment within 12 weeks prior to Week 1
  • Major surgery within 3 months prior to Week 1
  • Presence of other illness
  • Other inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    SRP-4045

    Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).

    Drug: SRP-4045

  • Experimental
    SRP-4053

    Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).

    Drug: SRP-4053

  • Placebo comparator
    Placebo followed by SRP-4045 or SRP-4053

    Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).

    Drug: SRP-4045 · Drug: SRP-4053 · Drug: Placebo

Interventions

  • DrugCasimersenStudies of CasimersenCasimersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SRP-4045 solution for IV infusion

    Also known as: Casimersen, AMONDYS 45

  • DrugGolodirsenStudies of GolodirsenGolodirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SRP-4053 solution for IV infusion

    Also known as: Golodirsen, VYONDYS 53

  • DrugPlacebo

    SRP-4045 or SRP-4053 placebo-matching solution for IV infusion

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 4-Step Ascend Velocity at Week 96

    Time frame: Baseline, Week 96

Secondary outcomes

  1. Change from Baseline in the Total Distance Walked During 6MWT at Week 96

    Time frame: Baseline, Week 96

  2. Change from Baseline in Rise from Floor Velocity at Week 96

    Time frame: Baseline, Week 96

  3. Change From Baseline in the 4-Step Ascend Velocity at Week 144

    Time frame: Baseline, Week 144

  4. Change From Baseline in Total Distance Walked During the 10-meter walk/run (10-MWR) Velocity

    Time frame: Baseline, Week 96

  5. Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 96

    The NSAA is a clinician administered scale that rates the participant's performance on various functional activities. During this assessment, participants will be asked to perform 17 different functional activities, including a 10 meter walk/run, rising from a sit to standing, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participants will be graded as follows: 2 = achieves goal without any assistance; 1 = modified method but achieves goal independent of physical assistance from another person; and 0 = unable to achieve goal independently. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.

    Time frame: Baseline, Week 96

  6. Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Weeks 48 or 96

    Time frame: Baseline, Week 48 or Week 96

  7. Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Weeks 48 or 96

    Time frame: Baseline, Week 48 or Week 96

07

Study locations

76 sites
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • David Geffen School of Medicine, UCLA
    Los Angeles, California 90095, United States
  • Rady Children's Hospital San Diego/ UCSD
    San Diego, California 92123, United States
  • Stanford University School of Medicine/Medical Center
    Stanford, California 94305, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • NW Florida Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Center for Integrative Rare Disease Research (CIRDR)
    Atlanta, Georgia 30318, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • University of Kansas, Medical Center
    Kansas City, Kansas 66160, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • University of Rochester Clinical Research Center
    Rochester, New York 14642, United States
  • Cincinnati Children's Hospital Medical Center (CCHMC)
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Shriners Hospital for Children
    Portland, Oregon 97239, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • DOM Centro de Reumatologia
    Buenos Aires, 1111, Argentina
  • Royal Children's Hospital Melbourne
    Parkville, Victoria 3052, Australia
  • Queensland Children's Hospital
    South Brisbane, 4101, Australia
  • Children's Hospital at Westmead
    Westmead, 2145, Australia
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • CHR de la Citadelle
    Liège, 4000, Belgium
  • University Multiprofile Hospital for Active Treatment Aleksandrovska EAD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Alberta Childrens Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Children's and Women's Health Centre of British Columbia
    Vancouver, British Columbia V6H 3V4, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • University Hospital Brno
    Brno, 61300, Czechia
  • Fakultni nemocnice v Motole
    Prague, 15008, Czechia
  • Rigshospitalet Copenhagen University Hospital
    København Ø, 2100, Denmark
  • Hôpital Des Enfants
    Toulouse, Haute-Garonne 31059, France
  • Reference Centre for Neuromuscular Diseases
    Nantes, 44093, France
  • Hôpital Armand Trousseau
    Paris, 75012, France
  • LMU Klinikum der Universität
    München, Bavaria 80337, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • University Hospital Freiburg
    Freiburg im Breisgau, 79106, Germany
  • IASO Children's Hospital
    Marousi, 15123, Greece
  • Ippokratio General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • Semmelweis Egyetem Genomikai Medicina és Ritka Betegsegek Intezete
    Budapest, 1083, Hungary
  • Royal Instituite of Child Neurosciences
    Ahmedabad, Gujarat 380054, India
  • Deenanth Mangeshkar Hospital
    Pune, Maharashtra 411004, India
  • The Children's University Hospital
    Dublin, D1, Ireland
  • Schneider Children's Medical Center of Israel
    Petah Tikvah, 49102, Israel
  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
    Ferrara, 44124, Italy
  • Istituto Giannina Gaslini
    Genoa, 16147, Italy
  • Az Ospedaliera Universitaria Policlinico G Martino
    Messina, 98125, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
  • Policlinico Universitario A Gemelli
    Rome, 00168, Italy
  • Neurociencias Estudios Clínicos S.C
    Culiacán, 80020, Mexico
  • Instituto de Investigaciones Clínicas para la Salud A.C
    Durango, 34000, Mexico
  • Samodzielny Publiczny Centralny Szpital Kliniczny
    Warsaw, Masovian Voivodeship 02-097, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Federal state budget educational institution of higher education "Russian national research medical university n.a. N.I. Pirogov" of Ministry of healthcare of Russian Federation
    Moscow, 125412, Russia
  • State Autonomous Healthcare Institution of Sverdlovsk Region Children's Clinical Hospital No. 9 City of Ekaterinburg
    Yekaterinburg, Russia
  • Clinic for Neurology and Psychiatry for Children and Youth
    Belgrade, 11000, Serbia
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Pusan National University Yangsan Hospital
    Yangsan, 50612, South Korea
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, Spain
  • Drottning Silvias Barn Och Ungdomssjukhus
    Gothenburg, SE-41685, Sweden
  • Royal Hospital for Children (Glasgow)
    Glasgow, G51 4TF, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS1 3EX, United Kingdom
  • Alder Hey Childrens Hospital
    Liverpool, L12 2AP, United Kingdom
  • Great Ormond Street Hospital (GOSH)
    London, WC1N 1EH, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Publications

  • Vandekerckhove I, Hanssen B, Peeters N, Dewit T, De Beukelaer N, Van den Hauwe M, De Waele L, Van Campenhout A, De Groote F, Desloovere K. Anthropometric-related percentile curves for muscle size and strength of lower limb muscles of typically developing children. J Anat. 2025 Aug;247(2):348-362. doi: 10.1111/joa.14241. Epub 2025 Mar 17. PubMed 40098309 ↗
  • Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021 Sep;64(3):285-292. doi: 10.1002/mus.27347. Epub 2021 Jun 29. PubMed 34105177 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2024, 97 months.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 97 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2015
First posted
Jul 16, 2015
StartActual
Sep 28, 2016
Primary completionActual
Nov 12, 2024
CompletionActual
Oct 16, 2025
Results delay requested
Sep 3, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02500381
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Sep 28, 2016
Primary completion
Nov 12, 2024
Completion
Oct 16, 2025
Last update
Nov 18, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Casimersen · Golodirsen

Start the discussion